Single‐arm trials for US Food and Drug Administration cancer drug approvals
Cancer · 2023
DOI: 10.1002/cncr.34830 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer, 2023. Verfasst von Mary Beth Nierengarten. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit nennt 3 Literaturangaben.
Abstract (Originalsprache)
This news section offers Cancer readers timely information on events, public policy analysis, topical issues, and personalities. In this issue, we explore why using single‐arm studies for accelerated US Food and Drug administration approvals can help get drugs previously approved for other uses to patients with cancer. In addition, new studies show that adherence to evidence‐based surgical metrics improves long‐term outcomes in patients with early‐stage lung cancer, and lung cancer screening based on personal lung cancer risk is more cost‐effective than screening based on age and smoking history.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Nierengarten, M. B. (2023). Single‐arm trials for US Food and Drug Administration cancer drug approvals. Cancer. https://doi.org/10.1002/cncr.34830
Vancouver
Nierengarten MB. Single‐arm trials for US Food and Drug Administration cancer drug approvals. Cancer. 2023. doi:10.1002/cncr.34830
BibTeX
@article{Nierengarten2023,
author = {Nierengarten, Mary Beth},
title = {Single‐arm trials for US Food and Drug Administration cancer drug approvals},
journal = {Cancer},
year = {2023},
doi = {10.1002/cncr.34830}
}
EUVIMED